BIL vs IBB
SPDR Bloomberg 1-3 Month T-Bill ETF vs iShares Biotechnology ETF
BIL$91.50
SPDR Bloomberg 1-3 Month T-Bill ETF
Ultra-short T-Bills, cash-equivalent.
Expense: 0.14%Yield: 3.66%
IBB$217.75
iShares Biotechnology ETF
NASDAQ biotech and pharmaceutical companies.
Expense: 0.44%Yield: 0.16%
Quick take
- • BIL has the lower expense ratio at 0.14% vs 0.44% for IBB.
- • BIL pays a higher dividend yield (3.66%).
Side-by-side metrics
| Metric | BIL | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.14% | 0.44% |
Dividend yield Trailing 12-month yield. | 3.66% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $48.51B | $11.50B |
YTD return | 3.12% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.00 | 0.60 |
P/E ratio | — | 25.48 |
Last price | $91.50 | $217.75 |
Inception | — | — |
Issuer | State Street | iShares |
BIL top holdings
Holdings data unavailable for BIL.
IBB top holdings
Top holdings · IBB
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
Sector breakdown · IBB
Healthcare100.0%
About BIL
BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) is Ultra-short T-Bills, cash-equivalent. Managed by State Street, the fund carries $48.5B in assets under management, an expense ratio of 0.14%, a dividend yield of 3.66%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.